TNF and inflammatory bowel disease: As patients with IBD treated with anti-IL-12/23 were largely indistinguishable from people in the healthy control group in their Ab responses and MBC phenotypes yet have the same age distribution and disease state as the patients treated with anti-TNF, with the majority in remission at the time of the study, they serve as an ideal control to assess the effect of anti-TNF treatment, independent of any effects of disease.